ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patientsTeodoro Vargas, Ana Ramı́rez de Molina, Juan Moreno‐Rubio et al.|Oncotarget|2015Cited by 76
Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, David Ramos et al.|Molecular Cancer Therapeutics|2014Cited by 12
European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.Joost L. Boormans, Pilar Laguna, Richard Sylvester et al.|Journal of Clinical Oncology|2023Cited by 4
PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia.Carlos Fernández-Martos, Ruth Vera, Jorge Aparicio et al.|Journal of Clinical Oncology|2018Cited by 0
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Unknown|2023Cited by 0